TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

4.70$ -9.9% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Prime Medicine, Inc. (PRME)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.9% of the shares are freely tradable; institutional investors hold 66.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 66.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 23.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 61.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 22.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 181Mio.

Largest Shareholders

Institutions

Institutions PRME
Name Stake (%) Shares Change (%) Date
Alphabet Inc 9.13 16,562,498 +0.0 06/30/2026
BlackRock Inc 5.29 9,602,041 +12.9 06/30/2026
ARK Investment Management LLC 4.60 8,348,746 +33.6 06/30/2026
State Street Corp 4.18 7,576,460 +19.4 06/30/2026
T. Rowe Price Investment Management,Inc. 2.89 5,237,332 -4.5 06/30/2026
Vanguard Capital Management, LLC 2.49 4,522,640 +1.1 06/30/2026
Balyasny Asset Management LLC 2.19 3,969,082 -3.7 06/30/2026
The Goldman Sachs Group Inc 1.89 3,430,518 +253.5 06/30/2026

Funds

Funds PRME
Name Stake (%) Shares Change (%) Date
ARK Genomic Revolution ETF 4.20 7,615,895 +0.2 09/30/2026
State Street® SPDR® S&P® Biotech ETF 2.01 3,641,764 -1.9 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?